Navigation Links
Hepatitis E Diagnostic Tests Market Worth 60.4 Million USD by 2024: Fueled by Lack of Potable Water, Hepatitis E Hyperendemicity to Drive Growth, Reports TMR
Date:11/18/2016

ALBANY, New York, November 18, 2016 /PRNewswire/ --

Driven by a small number of players, the global market for Hepatitis E Diagnostic Tests exhibits a highly competitive landscape, finds a new report by Transparency Market Research (TMR). With a share of nearly 31%, Beijing Wantai Biological Pharmacy led the global market in 2015 and was distantly followed by Mikrogen. Competitive pricing strategy among the leading players is expected to intensify the rivalry within the market in the forthcoming years. 

According to the research report, the global hepatitis E diagnostic tests market stood at US$43.7 mn in 2015. Expanding at a CAGR of 3.80% during the period from 2016 to 2024, the opportunity in this market is likely to increase to US$60.4 mn by the end of the forecast period. Being the primary test for the detection of hepatitis E, the kits used for ELISA HEV IgM tests have been the most valued diagnostic kits in this market in the recent past and will continue to be so due to the same reason. 

Inquire for a Sample Copy of Research Report: http://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=16859

Hepatitis E Hyperendemicity in Asian Economies to Ensure Dominance of Asia Pacific Region

The research report has also analyzed the worldwide market for hepatitis E diagnostic tests on the basis of geography. According to the study, Europe, Asia Pacific, Latin America, North America, and the Middle East and Africa have surfaced as the main regional markets for hepatitis E diagnostic tests across the world. 

Due to the hyperendemicity of hepatitis E in various Asian economies, such as Nepal, Pakistan, India, Vietnam, Bangladesh, Bhutan, Burma, Kazakhstan, and Thailand, Asia Pacific has surfaced as the leading regional market for hepatitis E diagnostic tests and is expected to remain so over the forecast period. The Asia Pacific market for hepatitis E diagnostic tests is likely to acquire more than 48% of the overall market by 2024. 

Besides, the Middle East and Africa is also projected to witness a significant rise in the market for the hepatitis E diagnostic tests over the next few years due to the increasing prevalence of hepatitis E in various countries in this region, such as Kenya, Morocco, Uganda, and Nigeria, owing to lack of safe drinking water and poor sanitation facilities. 

Growing Prevalence of Hepatitis E to Boost Demand

"The growth of the global market for hepatitis E is directly proportional to the prevalence of hepatitis E across the world," says the author of this study. As per the WHO, nearly 20 million people suffer from HEV infections every year, worldwide, among which around 3.3 million are symptomatic cases. 

With the increasing scarcity of potable water and the lack of sanitation, the cases of hepatitis E infection is likely to increase considerably over the forthcoming years and will result in a substantial rise in the need for hepatitis E diagnostic test in the near future, states the research report. 

Get Discounts on Report Purchase: http://www.transparencymarketresearch.com/sample/sample.php?flag=D&rep_id=16859

Rising Incidence of Asymptomatic Diseases to Hamper Market's Growth

Although the worldwide market for hepatitis E diagnostic tests currently looks teeming with opportunity, it may face a severe challenge over the years to come from the rising incidence of asymptomatic diseases, which are difficult to diagnose. The low level of awareness among consumers is also expected to emerge as a restraining factor for the growth of this market in the long run, notes the study. 

The study presented here is based on a report by Transparency Market Research (TMR) titled "Hepatitis E Diagnostic Tests Market - Global Industry Analysis, Size, Share, Volume, Growth, Trends, and Forecast 2016 - 2024." 

The Hepatitis E Diagnostic Tests Market has been segmented as follows:

 By Test Type

  • ELISA HEV IgM Test kits
  • ELISA HEV IgG Test kits
  • RT-PCR Test kits
  • Others

By End User

  • Hospitals
  • Research Centers
  • Diagnostic Laboratories
  • Point of Care

By Geography

  • North America
    • U.S.
    • Canada
  • Europe
    • U.K.
    • Germany
    • Spain
    • France
    • Italy
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • Australia
    • Rest of Asia Pacific
  • Latin America
    • Brazil
    • Mexico
    • Rest of Latin America
  • Middle East and Africa
    • A.E.
    • South Africa
    • Rest of Middle East and Africa

Browse Related Research Report: 


  • Human Vaccines Market (Vaccine Type - Conjugate, Recombinant, Inactivated, Combination, and Attenuated; Product - Pneumococcal, Influenza, Hepatitis, HPV, Meningococcal, Rotavirus, Measles, Typhoid, and Combination; Age Group - Pediatrics, Adolescents, Adults, and Geriatrics; Distribution Channel - Hospital Pharmacies and Drugstores) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024
    http://www.transparencymarketresearch.com/human-vaccines-market.html

About Us: 

Transparency Market Research (TMR) is a U.S. based provider of syndicated research, customized research, and consulting services. TMR's global and regional market intelligence coverage includes industries such as pharmaceutical, chemicals and materials, technology and media, food and beverages, and consumer goods, among others. Each TMR research report provides clients with a 360-degree view of the market with statistical forecasts, competitive landscape, detailed segmentation, key trends, and strategic recommendations.


Contact Us:
Transparency Market Research
90 State Street, Suite 700
Albany, NY 12207
Tel: +1-518-618-1030
USA - Canada Toll Free: 866-552-3453
Email: sales@transparencymarketresearch.com

Website: http://www.transparencymarketresearch.com

Blog: http://www.tmrblog.com/


'/>"/>
SOURCE Transparency Market Research
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Primary Efficacy and Safety Findings from Phase 3 Study of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
2. Hepatitis Awareness: Bringing Attention to a Silent Epidemic
3. Hepatitis C Drug Market: Forecasts for 9 Countries, Players (Current and Future) Analysis in New Research Reports
4. Baby Boomers Should Get Tested for Hepatitis C
5. Sorrento Therapeutics and Ben-Gurion University Sign an Agreement for the Development of Anti-Hepatitis C Virus Antibodies
6. Research Revealed on World Hepatitis Day Shows Countries Ill-equipped to Cope With Silent Epidemic
7. Am Welt-Hepatitis-Tag veröffentlichte Forschungsergebnisse zeigen, dass Länder die schleichende Epidemie unzureichend bekämpfen
8. TechAtlas Group Releases Hepatitis C Competitive Landscape Analysis
9. Roche and Inovio Pharmaceuticals partner on Inovios prostate cancer and hepatitis B immunotherapy products
10. Boehringer Ingelheim Expands Investigation of Interferon-free Hepatitis C Treatment Regimens to Reach More Patient Types through Presidio Pharmaceuticals Clinical Collaboration
11. BioLineRx Announces Receipt of a Notice of Allowance from USPTO for Patent on Use of BL-8020, an Oral, Interferon-Free Treatment for Hepatitis C
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/7/2017)... 2017 NuvoAir (formerly called Pond Healthcare ... a partnership with Novartis Pharma AG to distribute NuvoAir,s spirometry ... the leading mobile spirometry platform and Novartis, commitment to address ... ... ...
(Date:9/6/2017)... 2017  Robert G. Szewc, M.D., is recognized by ... recognition of his contributions to the Medical field.      ... at the practice of Kidney and Hypertension Specialists, which ... hypertension solutions. He has worked in this position since ... as well as expertise in kidneys, hypertension, chronic disease ...
(Date:9/6/2017)... 6, 2017 NeuroRx, a clinical stage biopharma company ... Behavior (ASIB), has been granted Fast Track status by the ... NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone). The ... of this sequential therapy targeting patients who are admitted to ... ...
Breaking Medicine Technology:
(Date:9/25/2017)... ... September 25, 2017 , ... The Byron Eaton Agency, ... the central Alabama region, is organizing a local charity drive to send money and ... 11 trillion gallons of water have fallen on Houston as a result of Hurricane ...
(Date:9/25/2017)... ... September 25, 2017 , ... ... international competition, were announced on Friday, September 22 during a gala event in ... resources professionals, teams, achievements and HR-related products and suppliers who help to create ...
(Date:9/25/2017)... Groton, CT and College Station, TX (PRWEB) , ... ... ... in prefabricated, flexible cleanroom solutions, will further expand its Portable, Continuous, Miniature, and ... and integrating them into the existing POD-based Oral Solid Dosage line. The new ...
(Date:9/25/2017)... ... September 25, 2017 , ... Lean ... efficiency. The principle of First-Defect-Stop for laboratory weighing is designed to ... the chance to have negative consequences on downstream processes. , If a problem ...
(Date:9/25/2017)... Pigeon, MI (PRWEB) , ... September 25, 2017 , ... ... and pallet solution. It is as simple as scanning the bar code of ... data is sent to a secure internet cloud where violations are automatically generated and ...
Breaking Medicine News(10 mins):